Iradimed (IRMD) Cash from Operations (2013 - 2026)

Iradimed (IRMD) has reported Cash from Operations for 14 consecutive years, with $5.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 23.33% year-over-year to $5.9 million in Q2 2026; TTM through Jun 2026 was $27.1 million, a 0.01% change from a year earlier, with the FY2025 full-year figure at $24.9 million, down 2.64% from the prior year.
• Cash from Operations was $5.9 million for Q2 2026 at Iradimed, down from $8.3 million in the prior quarter.
• Over five years, Cash from Operations peaked at $9.1 million in Q3 2024 and troughed at $1.4 million in Q3 2023.
• A 5-year average of $4.9 million and a median of $4.5 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 64.64% in 2023 and jumped 554.54% in 2024, its largest moves.
• Over 5 years, Cash from Operations stood at $3.0 million in 2022, then advanced by 28.75% to $3.9 million in 2023, then surged by 53.01% to $6.0 million in 2024, then retreated by 1.07% to $5.9 million in 2025, then gained by 0.29% to $5.9 million in 2026.
• The last three Cash from Operations figures came in at $5.9 million (Q2 2026), $8.3 million (Q1 2026), and $5.9 million (Q4 2025), per Business Quant data.